Cheungpasitporn, Wisit

Abstract Aim The objective of this meta‐analysis was to compare the effects of off‐pump and on‐pump coronary artery bypass grafting ( CABG ) on acute kidney injury ( AKI ) and the need of dialysis after surgery. Methods Comprehensive literature searches for randomized controlled trials ( RCTs ) of CABG with on‐pump and off‐pump was performed using MEDLINE , EMBASE , C ochrane D atabase of S ystematic R eviews, C ochrane C entral R egister of C ontrolled T rials S ystematic R eviews and clinicaltrials.gov from inception through S eptember 2014. Primary outcomes were the incidence of AKI and the need of dialysis. Mortality was assessed among the studies that reported renal outcomes. Pooled risk ratios ( RR s) and 95% confidence interval ( CI ) were calculated using a random‐effect, generic inverse variance method. Results Thirty‐three RCTs with 17 322 patients were enrolled in our study. Patients in the off‐pump CABG group had overall lower incidence of AKI (19.1%) compared with the on‐pump CABG group (22.2%). There was a protective effect of off‐pump CABG on the incidence of AKI compared with the on‐pump CABG group ( RR : 0.87; 95% CI : 0.77–0.98). However, there was no significant difference in the need for dialysis in the off‐pump group compared with the on‐pump group ( RR : 0.84; 95% CI 0.63–1.13). Within the selected trials, post hoc analysis assessing the mortality outcome demonstrated a pooled RR of 0.97 (95% CI , 0.77–1.23) in off‐pump versus on‐pump CABGs . Conclusions Our study demonstrates a beneficial effect of off‐pump CABG on the incidence of AKI . However, our meta‐analysis does not show benefits of the need of dialysis or survival among patients undergoing off‐pump CABG .

AbstractBackgroundThe reported risk of depression in patients with hypomagnesaemia is controversial.AimThe objective of this meta‐analysis was to assess the association between depression and hypomagnesaemia.MethodsA literature search was performed using MEDLINE, EMBASE, Cochrane Database and clinicaltrials.gov from inception through October 2014. Studies that reported odds ratios, relative risks or hazard ratios comparing the risk of depression in patients with hypomagnesaemia were included. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random‐effect, generic inverse variance method.ResultsSix observational studies (three cohort studies, two cross‐sectional studies and a case–control study) with a total of 19 137 patients were identified and included in the data analysis. The pooled RR of depression in patients with hypomagnesaemia was 1.34 (95% CI, 1.01–1.79, I2 = 33%). The association between depression and hypomagnesaemia was marginally insignificant after the sensitivity analysis including only cohort and case–control studies, with a pooled RR of 1.38 (95% CI, 0.92–2.07, I2 = 24%).ConclusionOur study demonstrates a potential association between hypomagnesaemia and depression. Further studies assessing the benefits of treatment of hypomagnesaemia in patients with depression are needed.

AbstractAimData on clinicopathological features, treatment and outcomes of IgA nephropathy (IgAN) in elderly patients are limited.MethodsNative kidney biopsies with a pathological diagnosis of IgAN (n = 1084) from Mayo Clinic Rochester in the years 1994–2013 were examined. After exclusion of the secondary IgAN, 45 elderly IgAN patients (age ≥65 years) were identified. One hundred sixty‐two younger adults (age 18–64 years) with IgAN were randomly selected for comparison.ResultsCompared with younger adults, elderly patients showed a higher rate of chronic hypertension (62.2 vs 27.2%), higher pulse pressures (65 ± 17 vs 51 ± 15 mmHg), requiring greater number of antihypertensive medications (2.5 ± 1.2 vs 1.7 ± 0.7) and lower blood haemoglobin (11.1 ± 2.3 vs 12.7 ± 2.1 g/dL) at time of kidney biopsy, all P < 0.001. Pathologically, elderly kidneys showed a higher degree of tubulointerstitial fibrosis (P = 0.04) and vascular sclerosis (P < 0.001). Treatments (including the use of angiotensin‐converting enzyme inhibitor (ACEI) inhibitor, angiotensin II receptor blocker (ARB) and immunosuppressants) were similar in the two cohorts. Elderly patients had more end‐stage renal disease at 6 months (HR 5.51; 95% CI 1.46–22.3, P = 0.01) and higher 6‐month and 5‐year mortality (HR 2.31; 95% CI 1.04–5.17, P = 0.04) after adjusting the age and comorbidities.ConclusionIgAN diagnosed at age >65 years tends to have a faster renal disease progression and higher patient mortality.

Abstract Background/Objectives The risk of chronic kidney disease ( CKD ) in patients who regularly drink soda is controversial. The objective of this meta‐analysis was to evaluate the associations between consumption of sugar‐sweetened and artificially sweetened soda and CKD . Methods A literature search was performed using MEDLINE , EMBASE and the C ochrane D atabase of S ystematic R eviews from inception until 30 J une 2014. Studies that reported odds ratios or hazard ratios comparing the risk of CKD in patients consuming significant amounts of either sugar‐sweetened or artificially sweetened soda versus those who did not consume soda were included. Pooled risk ratios ( RR ) and 95% confidence intervals ( CI ) were calculated using a random‐effects, generic inverse variance method. Results Five studies were included in our analysis of the association between consumption of sugar‐sweetened soda and CKD . The pooled RR of CKD in patients consuming sugar‐sweetened soda was 1.58 (95% CI 1.00–2.49). Four studies were selected to assess the association between consumption of artificially sweetened soda and CKD . The pooled RR of CKD in patients consuming artificially sweetened soda was 1.33 (95% CI 0.82–2.15). Conclusions Our study demonstrates statistically significant increased risks of CKD in patients consuming sugar‐sweetened soda, but not in patients consuming artificially sweetened soda. This finding suggests that sugar‐sweetened soda consumption is associated with CKD and may impact clinical management and primary prevention of CKD in high‐risk patients.

AbstractA possible causal relationship between sarcoidosis and malignancy has been the subject of debates for decades. To better understand this association, we conducted a systematic review and meta‐analysis of cohort studies that reported relative risk, hazard ratio or standardized incidence ratio with 95% confidence interval (CI) comparing the incidence of malignancy in patients with sarcoidosis versus non‐sarcoidosis participants. Pooled risk ratios (RR) and 95% CI were calculated using a random‐effect, generic inverse variance methodology. Five studies were identified and included in our data analyses. The pooled RR of malignancy in patients with sarcoidosis was 1.21 (95% CI: 1.04–1.40). However, when we performed a sensitivity analysis that included only studies that compared the incidence of malignancy after the first year of the diagnosis of sarcoidosis with the incidence of malignancy after the first year of index date for non‐sarcoidosis controls, the pooled risk ratio decreased and did not reach statistical significance (RR 1.13, 95% CI: 0.97–1.32). Furthermore, analysis for publication bias has suggested that publication bias in favour of positive studies may be present. In conclusion, after accounting for possible detection bias and publication bias, there does not appear be a significant association between sarcoidosis and malignancy.